The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
Abstract
PURPOSE: This phase III study was designed to demonstrate equivalence in survival of oral uracil/tegafur (UFT) and oral leucovorin (LV) to conventional intravenous (IV) fluorouracil (5-FU) and LV in previously untreated metastatic colorectal carcinoma. Safety was also compared. PATIENTS AND METHODS: Eight hundred sixteen patients were randomized to receive either UFT (300 mg/m 2/d) and LV (75 or 90 mg/d) for 28 days every 35 days or IV bolus 5-FU (425 mg/m 2/d) and LV (20 mg/m 2/d) for 5 days every 28 days. RESULTS: UFT/LV produced survival comparable to the IV 5-FU/LV regimen. Median survival was 12.4 months (95% confidence interval [CI], 11.2 to 13.6 months) with UFT/LV and 13.4 months (95% CI, 11.6 to 15.4 months) with 5-FU/LV (P = .630). The hazard ratio for survival was 0.964 (95.6% CI, 0.826 to 1.125), supporting equivalent survival. The overall response rate did not differ between treatment arms (UFT/LV, 11.7%; 5-FU/LV, 14.5%; P = .232). Median time to progression favored 5-FU/LV (UFT/LV, 3.5 months; 5-FU/LV, 3.8 months; P = .011), but tumor assessment schedules differed between arms. UFT/LV significantly improved safety compared with 5-FU/LV. Diarrhea, nausea and vomiting, and stomatitis and mucositis were significantly less frequent with UFT/LV, as was myelosuppression. Patients treated with UFT/LV had fewer episodes of febrile neutropenia (P < .001) and documented infections (P < .05). Increased bilirubin, without other liver function abnormalities, was observed more often with UFT/LV (P < .001). Concomitant medications were more frequent with 5-FU/LV, including use of antibiotics, growth factors, and antiemetics. CONCLUSION: UFT/LV provided a safer, more convenient oral alternative to a standard bolus IV 5-FU/LV regimen for metastatic colorectal cancer while producing equivalent survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationde Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Pazdur, R., Lassere, Y., Rhodes, V, Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Markowitz, A. B., Abbruzzese, J. L., & Bready, B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2296 · Cited by 205
Report on nationwide pooled data and cohort investigation in UFT phase II study
Ota, K., Taguchi, T., & Kimura, K. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254241 · Cited by 179
Ho, D. H., Pazdur, R. M., Covington, W., et al. (1998) · PubMed · Cited by 124
Saltz, L. B., Leichman, C. G., Young, C. W., Muggia, F. M., Conti, J. A., Spiess, T., Jeffers, S., & Leichman, L. P. (1995) · Cancer · Cited by 95
Гиллер, С. А., Zhuk, R. A., & Lidak, M. I. (1967) · PubMed · Cited by 86
González‐Barón, M., Feliú, J., de la Gándara, I., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00487-4 · Cited by 82
Uracil and tegafur modulated with leucovorin
Feliú, J., Bar�n, M. G., Espinosa, E., Gir�n, C. G., la G�ndara, I. D., Espinosa, J., Colmenarejo, A., Jal�n, J. I., Fern�ndez, Y., de Castro, J., et al. (1997) · Cancer · Cited by 69
Meropol, N. J., Rustum, Y. M., Petrelli, N. J., et al. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050432 · Cited by 62
Phase II trial of UFT in advanced colorectal and gastric cancer
Malik, S., Talbot, D. C., Clarke, P., et al. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.431 · Cited by 60
Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
Toide, H., Akiyoshi, H., Minato, Y., Okuda, H., & Fujii, S. (1977) · PubMed · Cited by 60
King, M. T., Dobson, A. J., & Harnett, P. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)89258-4 · Cited by 51
MacKay, H. J., Hill, M. E., Twelves, C. J., Glasspool, R. M., Price, T. J., Campbell, S., Massey, A., Macham, M. A., Uzzel, M., Bailey, S., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg340 · Cited by 41
Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule
Pazdur, R. M., Lassere, Y., Diaz-Canton, E. A., et al. (1997) · Investigational New Drugs · doi:10.1023/a:1005808822565 · Cited by 38
Tirapazamine-cisplatin: the synergy
Gatzemeier, U., Rodriguez, G., Treat, J., Miller, V., von Roemeling, R., Viallet, J., & Rey, A. A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.431 · Cited by 34
Tegafur-Uracil (UFT) Plus Folinic Acid in Advanced Rectal Cancer
Sanchíz, F., & Milla, A. (1994) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039730 · Cited by 32
Cao, S., Frank, C., Shirasaka, T., & Rustum, Y. M. (1995) · PubMed · Cited by 28
Rustum, Y. M. (2009) · Oncology · doi:10.1159/000227738 · Cited by 24
Abad, A., Navarro, M., Sastre, J., et al. (1997) · PubMed · Cited by 22
Bobbio-Pallavicini, E., Porta, C., Moroni, M., Spaghi, A., Casagranda, I., & Nastasi, G. (1993) · Journal of Chemotherapy · doi:10.1080/1120009x.1993.11739210 · Cited by 22
Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.
Barón, M. G., Feliú, J., Ordoñez, A., et al. (1993) · PubMed · Cited by 22
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Metadata
- Authors
- Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., & Benner, S. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-01
- Volume
- 20
- Issue
- 17
- Pages
- 3605-3616
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166127437
- Cited by
- 323
- References
- 31
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.